RGLS — Regulus Therapeutics Share News
0.000.00%
Last trade - 00:00- $563.57m
- $498.20m
Regulus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Regulus Therapeutics Reports Fourth Quarter And Year-End 2021 Financial Results And Recent Updates
Regulus Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Regulus Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview
Brief: Regulus Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Trial Of Lademirsen
Brief: Regulus Therapeutics Announces Successful Completion Of Pre-Ind Meeting With FDA For Rgls8429
Brief: Regulus Therapeutics Inc - On December 31, 2021, Co Entered Into An Eleventh Amendment To Its Loan And Security Agreement
Brief: Regulus Appoints Mohammad AhmadianAs Vice President, Chemistry And Pharmaceutical Development
Brief: Regulus Therapeutics Inc Files For Resale Of Up To 96.2 Mln Shares Of Common Stock By The Selling Stockholders
Brief: Regulus Therapeutics Announces Private Placement Of Equity
Regulus Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Regulus Therapeutics Posts Q3 Loss Per Share Of $0.10
Regulus Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-BlackRock, Delta Air Lines, Neuronetics, Regulus Therapeutics
Regulus Therapeutics slides after co scraps trial of kidney disorder treatment
U.S. STOCKS ON THE MOVE-Qualcomm, Revance Therapeutics, gold miners
Brief: Regulus Therapeutics Announces Strategic Prioritization Of Polycystic Kidney Disease Treatment
NASDAQ RESUMED AT 04:35 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:09 PM